AAIFNC 2024 Annual Symposium

San Francisco, CA US
April 27, 2024

The 2024 Bridges to Understanding program will provide continuing medical education on Food Allergy and Diagnosis, Anaphylaxis, treatment options in AERD, Asthma (childhood asthma and precision medicine), Mast Cell Disorders, and Immunodeficiency. Its goal is to promote knowledge and understanding of allergies, asthma, and clinical immunology through advocacy and education.  

The Allergy, Asthma & Immunology Foundation of Northern California (AAIFNC) is a nonprofit Foundation whose members are physicians and other medical professionals specializing in allergy and immunology. Our primary purpose is to encourage the association of medical professionals specializing in allergy, asthma, and immunology to study current issues and developments relevant to the specialty and the continuing education of those medical professionals. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma and Immunology Foundation of Northern California (AAIFNC).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239 for 7.0 contact hours.

Target Audience

Allied Health Professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…

1. Review current and future treatments in the management of food allergies. 
2. Understand how epigenetic mechanisms may influence the pathophysiological processes in asthma.
3. Evaluate strategies for treatment of chronic rhinosinusitis with nasal polyposis.
4. Review and understand treatment considerations for patients with hereditary angioedema.
5. Describe the efficacy, safety, and clinical decision-making for initiating and continuing venom immunotherapy.
6. Review diagnostic and treatment regimens for drug allergies.
7. Describe pathophysiology of sleep disorders and effects on the upper airway.
8. Understand clinical considerations in managing asthma in pregnancy.

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
  • 7.00 CBRN
Course opens: 
Course expires: 
Event starts: 
04/27/2024 - 8:00am CDT
Event ends: 
04/27/2024 - 5:00pm CDT

2024 Annual Symposium
Bridges to Understanding

April 27, 2024

6:15AM-8:15AM Registration, Exhibits & Coffee Break

8:15AM-8:20AM PROGRAM INTRODUCTION and WELCOME, Steve Machtinger, MD – AAIFNC President Session Moderator: Steve Machtinger, MD

8:20AM-9:10AM Venom Immunotherapy,Jonathan Matz, MD

9:10AM-10:00AM Asthma Epigenetics. David A. Schwartz, MD

10:00AM-10:50AM Asthma in Pregnancy, Jennifer Namazy, MD

10:50AM-11:20AM Exhibits, Posters, Coffee Break

11:20AM-12:10PM Upper Airway Resistance, the Young, and Evolution of OSA Syndrome, Shannon Sullivan, MD

12:10PM-1:00PM The Dark Side of Non-IgE Mediated Food Allergy Anna H. Nowak-Wegrzyn, MD, PhD

1:00PM-2:05PM Lunch Break & Exhibits

2:10PM-3:00PM Novel Insights into the Pathogenesis of Eosinophilic Nasal Polyposis and Implications for Treatment Larry Borish, MD

3:00PM-3:50PM Drug Allergy, Andrew A. White, MD

3:50PM-4:40PM HAE, Joshua S. Jacobs, MD

4:40PM-5:00PM Q&A

5:00PM-5:05PM Acknowledgements & Wrap-Up, Steve Machtinger, MD – AAIFNC President

Hotel Nikko
222 Mason Street
San Francisco, CA 94012
United States

All relevant financial relationships with ineligible companies have been mitigated.

The individuals listed below disclose the following financial relationships:

Larry Borish, MD, Speaker
Consultant: AstraZeneca, DevPro, GSK, Regeneron, Sanofi
Independent Contractor: Regeneron

Joshua S. Jacobs, MD, Speaker
Advisor: AstraZeneca, BioCryst, Regeneron, Takeda
Consultant: Genentech, Takeda
Contracted Research: Genentech, Ionis, Novartis, Pharvaris, Regeneron
Independent Contractor: AstraZeneca, CSL Behring
Speaker: AstraZeneca, BioCryst, Regeneron, Takeda
Stock ownership: Regeneron

Jonathan Matz, MD, Speaker
Contracted Research: Upstream Bio
Independent Contractor: Allergy Therapeutics, AstraZeneca, Chiesi, Cipla
Speaker: AstraZeneca

Jennifer Namazy, MD, Speaker
Independent Contractor: GSK

Anna H. Nowak-Wegrzyn, MD, PhD, Speaker
Advisor: Labcorp, Novartis
Researcher: DBV Technologies, Siolta
Speaker: Genentech, Nestle, Nutricia

Andrew White, MD, Speaker
Advisor: Amgen, AstraZeneca, Blueprint, Cogent Pharmaceuticals, GSK, Optinose, Regeneron/Sanofi
Researcher: AstraZeneca, Regeneron/Sanofi
Speaker: AstraZeneca, Blueprint, GSK, Optinose, Regeneron/Sanofi

Kristina Philpott, MD, Planner, Moderator
Stocks: Amgen, Eli Lilly, GSK, Illumina, Medtronic, Merck, Stryker, Thermo Fisher, Zoetis

Gregory Bensch, MD, Planner
Advisor: Aimmune, AstraZeneca, Sanofi/Regeneron
Consultant: Sanofi/Regeneron
Speaker: Aimmune, AstraZeneca, Blueprint, Incyte, Sanofi/Regeneron, Teva

The following have no relevant financial relationships with ineligible companies to disclose:

David Schwartz, MD, Speaker
Shannon Sullivan, MD, Speaker
Steve Machtinger, MD, Planner, Moderator
Javaid M. Khan, DO, Planner
A. Carmen Choy, MD, Planner
Seach McGhee, MD, PhD, Planner
Iris Otani, MD, Planner
Dai Park, MD, Planner
Michelle Huffaker, MD, Planner
Sarah Pederson, RN, Planner
Karol Anderson, Planner

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
  • 7.00 CBRN
Please login or create an account to take this course.